Investor Relations.
AIkido Pharma Inc. seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming events and presentations and financial documents. AIkido Pharma Inc. is traded on the Nasdaq under the ticker symbol AIKI.
Overview.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio
of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from
leading universities and researchers, and we are currently in the process of developing an innovative
therapeutic drug platform through strong partnerships with world renowned educational institutions,
including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline
of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-
spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.